Literature DB >> 17243490

Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2.

Patrizia Marini1.   

Abstract

Human Genome Sciences Inc, under license from Cambridge Antibody Technology Ltd, is developing lexatumumab, an intravenous human agonistic mAb to TNF-related apoptosis-inducing ligand (TRAIL) receptor 2, for the potential treatment of cancer. Phase II clinical trials of lexatumumab are underway.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17243490

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  5 in total

1.  A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.

Authors:  Nancy Lynn Booth; Thomas J Sayers; Alan D Brooks; Cheryl L Thomas; Kristen Jacobsen; Ekaterina I Goncharova; James B McMahon; Curtis J Henrich
Journal:  Cancer Immunol Immunother       Date:  2008-12-17       Impact factor: 6.968

2.  Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.

Authors:  Tanmoy Mondal; Gururaj N Shivange; Rachisan Gt Tihagam; Evan Lyerly; Michael Battista; Divpriya Talwar; Roxanna Mosavian; Karol Urbanek; Narmeen S Rashid; J Chuck Harrell; Paula D Bos; Edward B Stelow; M Sharon Stack; Sanchita Bhatnagar; Jogender Tushir-Singh
Journal:  EMBO Mol Med       Date:  2021-02-15       Impact factor: 12.137

Review 3.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

4.  Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

Authors:  Melinda S Merchant; James I Geller; Kristin Baird; Alexander J Chou; Susana Galli; Ava Charles; Martha Amaoko; Eunice H Rhee; Anita Price; Leonard H Wexler; Paul A Meyers; Brigitte C Widemann; Maria Tsokos; Crystal L Mackall
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

5.  Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

Authors:  H A Wakelee; A Patnaik; B I Sikic; M Mita; N L Fox; R Miceli; S J Ullrich; G A Fisher; A W Tolcher
Journal:  Ann Oncol       Date:  2009-07-24       Impact factor: 32.976
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.